Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New antibiotic match for tough UTIs?

NCT ID NCT03543436

Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested if the antibiotic temocillin works as well as a stronger antibiotic (carbapenem) for treating urinary tract infections caused by resistant bacteria. 29 hospitalized adults took part. The goal was to see if both treatments could clear the infection and symptoms. The study was completed and results may help guide future treatment choices.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

29 people

The number who actually took part.

Started

Jan 2019

Finished

Dec 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult (≥ 18 years) * Hospitalized patient with clinically significant monomicrobial UTI * Complicated UTI due to ESBL producing enterobacteriaceae (pyelonephritis, prostatitis or renal abscess) requiring parenteral antimicrobial therapy * Susceptibility to temocillin and carbapenem as evidenced by testing results * For woman able to procreate: negative pregnancy test and use of an effective method of contraception (abstinence, oral contraceptives, intra-uterine device, diaphragm with spermicide and condom). All forms of hormonal contraception are acceptable * Signed informed consent by patient himself (able or under curatorship) or his legal representative (patient unable to give his consent or under tutorship) * Patient affiliated to the social security system Exclusion Criteria: * Patient infected with a bacteria which is not an ESBL-producing enterobacteriaceae. * Polymicrobial infection. * Hypersensitivity and/or previous intolerance to carbapenem or temocillin, or penicillins or any other beta-lactam. * Patient with a contraindication to any of the drugs to be used in research * Patient presenting another site of infection than urinary (except onset of bacteraemia from urinary tract origin due to Gram negative bacteria). * Woman who is pregnant, breastfeeding, or expecting to conceive at any time during the study (pregnancy test will be conducted for woman without menopause). * Palliative care of life expectancy \< 90 days. * Ongoing empirical treatment of the urinary tract infections with carbapenem or temocillin \> 24 hours before randomization * Delay in randomization \> 48 hours after identification of ESBL producing enterobacteriaceae in urinary and/or blood culture. * Participation in other clinical trial for the infection.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Urinary tract infection due to extended-spectrum beta-lactamase producing enterobacteriaceae are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bacterial urinary tract infection urinary tract infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Urinary tract infections

Contacts and locations

Locations

  • APHP - Beaujon Hospital

    Paris, France

  • APHP - Cochin Hospital

    Paris, 75014, France

  • APHP - Georges Pompidou European Hospital

    Paris, France

  • APHP - Necker-Enfants maladies Hospital

    Paris, 75015, France

  • APHP - Saint-Antoine Hospital

    Paris, France

  • Bichat hospital

    Paris, 75018, France

  • CHRU La Cavale Blanche

    Brest, 29000, France

  • CHU Pontchaillou

    Rennes, 35000, France

  • CHU de Grenoble Hospital

    Grenoble, France

  • CHU de Martinique

    Fort-de-france, Martinique, France

  • CHU de Pau

    Pau, France

  • CHU de Poitiers

    Poitiers, France

  • Groupe Hospitalier Diaconesses Croix Saint Simon

    Paris, 75020, France

  • Melun Hospital - CHU Sud

    Melun, 77, France

  • Saint-Joseph Hospital

    Paris, France

  • Tenon Hospital

    Paris, 75020, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.